Organon – a women’s healthcare company spun off from Merck in June 2021 – has appointed Kirke Weaver as General Counsel and Corporate Secretary, effective January 1, 2023.
Weaver, who was named general counsel and interim head of the corporate secretary’s office in July, will also remain on the company’s executive leadership team in Jersey City.
Weaver brings nearly 20 years of experience in the pharmaceutical industry, having previously served as Executive Vice President, Commercial, Regulatory, Securities, Hiring and Deputy Corporate Secretary at Organon. The company says he played a key role in launching Organon as an independent company.
In a December 12 statement, Organon CEO Kevin Ali said that since transitioning to an interim role, Weaver “has contributed deep and invaluable expertise to guide Organon.” rice field.
“He brings excellence to this role, but above all embodies our values by ensuring our commitment to conduct business with ethics and integrity,” Ali added. I was.
Prior to joining Organon, Weaver was Vice President of Merck’s Office of General Counsel, which he joined in 2003.
He holds a bachelor’s degree from the College of William and Mary and a Juris Doctor degree from Yale Law School.
Weaver, who said he was thrilled to take on the permanent role, said, “I am committed to continuing to use my skills to solve important problems that affect women and, ultimately, society as a whole.” looking forward to it.”
Since its 2021 spin-off, the company has achieved significant milestones, including the acquisition of medical device company Alydia Health in June 2021 and clinical-stage drug development company Forendo Pharma in December 2021. . Organon’s net revenue in its first year was $6.3 billion.